2 Risky Gene-Editing Stocks to Buy in the New Bull Market if You Dare
With a fresh bull market in full swing, there's an opportunity to pick up shares of biotechs that were until recently, during the bear market, shedding their value like there was no tomorrow.
While young biotechs will still be as risky as ever, as the shift in sentiment can't drive revenue or help companies to nail their clinical trials or attempts to develop therapies, it's still a welcome change. And notching a positive catalyst might lead to much more upside for investors now than it did during the bear market.
So let's take a peek at two risky stocks that have as bright a future as is possible at their current level of maturity.
Source Fool.com
